ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

Interferon Results Cool Expectations, But Other Reports At ASCO/AACR Demonstrate Solid Progress

June 6, 1980

Regulatory Agencies: FDA Proposes “Treatment IDE” Funding Opportunities:

February 7, 1997

Robert Day Advocates NCI Payment for Investigator Salaries

May 7, 1999

DCT Advisors Reject MRS Concept, Approve RDOG Expansion

November 30, 1990

Nexavar Phase III Trial Fails To Meet Primary Endpoint

June 29, 2012

Moyniham Bill Will Direct HHS to Exempt Centers Recognized By NCI From Prospective Payment System

August 15, 1986